CA2366755A1 - Method of increasing bone volume using non-naturally-occurring ep, selective agonists - Google Patents

Method of increasing bone volume using non-naturally-occurring ep, selective agonists Download PDF

Info

Publication number
CA2366755A1
CA2366755A1 CA002366755A CA2366755A CA2366755A1 CA 2366755 A1 CA2366755 A1 CA 2366755A1 CA 002366755 A CA002366755 A CA 002366755A CA 2366755 A CA2366755 A CA 2366755A CA 2366755 A1 CA2366755 A1 CA 2366755A1
Authority
CA
Canada
Prior art keywords
naturally
occurring
agonist
bone
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002366755A
Other languages
English (en)
French (fr)
Inventor
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2366755A1 publication Critical patent/CA2366755A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002366755A 1999-03-05 2000-03-01 Method of increasing bone volume using non-naturally-occurring ep, selective agonists Abandoned CA2366755A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12306399P 1999-03-05 1999-03-05
US60/123,063 1999-03-05
PCT/US2000/005196 WO2000051585A2 (en) 1999-03-05 2000-03-01 Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume

Publications (1)

Publication Number Publication Date
CA2366755A1 true CA2366755A1 (en) 2000-09-08

Family

ID=22406507

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002366755A Abandoned CA2366755A1 (en) 1999-03-05 2000-03-01 Method of increasing bone volume using non-naturally-occurring ep, selective agonists

Country Status (10)

Country Link
EP (1) EP1158969A2 (ja)
JP (1) JP2002538105A (ja)
AU (1) AU3711900A (ja)
CA (1) CA2366755A1 (ja)
CO (1) CO5150205A1 (ja)
IL (1) IL145128A0 (ja)
NO (1) NO20014192L (ja)
NZ (1) NZ513828A (ja)
PE (1) PE20001552A1 (ja)
WO (1) WO2000051585A2 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118173A1 (ja) 2005-04-28 2006-11-09 Ono Pharmaceutical Co., Ltd. 経皮吸収製剤
EP2085088A4 (en) 2006-10-26 2012-08-29 Ono Pharmaceutical Co ADHESIVE PREPARATION
US20110038884A1 (en) 2008-04-28 2011-02-17 National University Co., Hamamatsu Univer. School Of Medicine Immunopotentiating agent comprising ep1 agonist
WO2011109729A2 (en) * 2010-03-05 2011-09-09 University Of Rochester Ep1 inhibition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3982016A (en) * 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
AU2146592A (en) * 1991-05-29 1993-01-08 Sepracor, Inc. Combination of nsaids and prostaglandins and uses therefor
WO1999012551A1 (en) * 1997-09-09 1999-03-18 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring fp selective agonists
JP2002527400A (ja) * 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨形成刺激方法
WO2000051616A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives

Also Published As

Publication number Publication date
NO20014192D0 (no) 2001-08-29
EP1158969A2 (en) 2001-12-05
JP2002538105A (ja) 2002-11-12
NO20014192L (no) 2001-11-05
IL145128A0 (en) 2002-06-30
WO2000051585A3 (en) 2001-01-25
CO5150205A1 (es) 2002-04-29
AU3711900A (en) 2000-09-21
WO2000051585A2 (en) 2000-09-08
NZ513828A (en) 2001-09-28
PE20001552A1 (es) 2001-01-30

Similar Documents

Publication Publication Date Title
US6156799A (en) Method of increasing bone volume using non-naturally-occurring FP selective agonists
JPH09505809A (ja) ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害
FR2774591A1 (fr) Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
NO335143B1 (no) Anvendelse av en 15-keto-prostaglandinforbindelse til fremstilling av et farmasøytisk preparat for behandling av legemiddelindusert forstoppelse, hvor den legemiddelinduserte forstoppelsen er opioid eller antikolinergika legemiddelindusert forstoppelse
JP2003523976A (ja) 眼圧降下脂質
EP1140054B1 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
CA2366755A1 (en) Method of increasing bone volume using non-naturally-occurring ep, selective agonists
CA2303799A1 (en) Method of increasing bone volume
WO2000051616A1 (en) Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
EP0351755A1 (en) Combination of a calcium channel blocker and thromboxane A2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination
WO2003070252A1 (fr) Agents antiprurigineux
JP5039236B1 (ja) 抗不整脈剤及び心房細動抑制剤
MXPA00002394A (en) Method of increasing bone volume using non-naturally-occurring fp selective agonists
MXPA00002395A (en) Method of increasing bone volume
JP2002520300A (ja) Ｇａｂａ類縁体及び抗ウイルス剤を含んでなる帯状ヘルペスを治療するための医薬組成物
JPH1135470A (ja) ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
CN1354676A (zh) 用于心血管疾病疗法的氨基四氢化萘衍生物
WO2009148163A1 (ja) 膀胱排尿筋収縮および尿道括約筋弛緩剤
CZ2000808A3 (cs) Použití selektivního FP agonisty, který se přirozeně nevyskytuje
JP2002538122A (ja) 天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法
JP5615868B2 (ja) 持続性心房細動モデル及びその製造方法、並びに、心房細動抑制剤のスクリーニング方法
Gillespie et al. Department of Physiological Sciences, The U'ntiversity Neucastle utpon Tyne NE2 4HH
MIYAZAKI et al. PHARMACOKINETIC PROPERTIES OF ANTI-HYPERTENSIVE DRUGS
CZ2000848A3 (cs) Sloučenina analogická prostaglandinu F a její použití

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued